Joseph J Schroeder, 40Boston, MA

6417162, Jul 9, 2002

May 7, 1999

09/306809

David S. Garvey - Dover MA
Joseph D. Schroeder - Boston MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

A01N 4354

514 2, 514258, 514259, 514260, 514280, 514423, 514562, 514644, 514645

The present invention is directed to nitrosated or nitrosylated -adrenergic receptor antagonists, compositions comprising -adrenergic receptor antagonists that are optionally substituted with at least one NO or NO moiety and compounds that donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and methods for treating sexual dysfunctions in males and females.

6433182, Aug 13, 2002

May 7, 1999

09/306805

David S. Garvey - Dover MA
Joseph D. Schroeder - Boston MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

C07D23500

5483017, 514 2, 514360, 514385

The present invention is directed to nitrosated or nitrosylated -adrenergic receptor antagonists, compositions comprising -adrenergic receptor antagonists that are optionally substituted with at least one NO or NO moiety and compounds that donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and methods for treating sexual dysfunctions in males and females.

6469065, Oct 22, 2002

Sep 1, 1999

09/387724

David S. Garvey - Dover MA
Joseph D. Schroeder - Dedham MA
Inigo Saenez de Tejada - Madrid, ES
Ricky D. Gaston - Malden MA
Tatiana E. Shelekhin - Acton MA
Tiansheng Wang - Concord MA

NitroMed, Inc. - Bedford MA

A61K 31135

514546, 514506, 514617, 514651, 536103, 540 1, 540147, 540155, 548500, 564 45

The present invention describes novel nitrosated and/or nitrosylated -adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated -adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one -adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

6514934, Feb 4, 2003

Mar 30, 1999

09/280540

David S. Garvey - Dover MA
Joseph D. Schroeder - Boston MA
Inigo Saenz de Tejada - Madrid, ES

NitroMed, Inc. - Bedford MA

A61K 3800

514 2, 514248, 514242, 514280, 514307, 514396, 514400, 514471, 514 18, 514509, 514523, 514532, 514649, 514684, 514929, 536 261, 424 851, 4241301, 5483351, 562560

The present invention is directed to nitrosated or nitrosylated -adrenergic receptor antagonists, compositions comprising -adrenergic receptor antagonists that are optionally substituted with at least one NO or NO moiety and compounds that donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and methods for treating sexual dysfunctions in males and females.

6593347, Jul 15, 2003

Aug 27, 2001

09/938560

Upul K. Bandarage - Newton MA
Qing Dong - Cambridge MA
Xinqin Fang - Chestnut Hill MA
David S. Garvey - Dover MA
Gregory J. Mercer - Stoughton MA
Stewart K. Richardson - Tolland CT
Joseph D. Schroeder - Dedham MA
Tiansheng Wang - Concord MA

NitroMed, Inc. - Bedford MA

A61K 31445

514327, 5142262, 514291, 514365, 514374, 514375, 514378, 514393, 514404, 514406, 514411, 514416, 514419, 514423, 514427, 514428, 514431, 514448, 514450, 514532, 514539, 514545, 514621, 514640, 514658, 514676, 514709, 514719

The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

6649629, Nov 18, 2003

Dec 22, 2000

09/741816

Upul K. Bandarage - Newton MA
Xinqin Fang - Lexington MA
David S. Garvey - Dover MA
L. Gordon Letts - Dover MA
Joseph D. Schroeder - Dedham MA
Sang William Tam - Dover MA

Nitromed, Inc. - Bedford MA

C07D207325

514326, 514378, 514406, 546209, 548247, 548248, 5483751, 548561

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B (LTB ) receptor antagonists, leukotriene A (LTA ) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

7166618, Jan 23, 2007

Jun 18, 2003

10/463671

Ramani R. Bandarage - Newton MA, US
David S. Garvey - Dover MA, US
L. Gordon Letts - Dover MA, US
Joseph D. Schroeder - Dedham MA, US
Sang William Tam - Dover MA, US

NitroMed, Inc. - Lexington MA

C07D 263/04
A61K 31/42
C07D 207/325

514327, 514376, 514509, 546221, 548231, 558482, 558488

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B(LTB) receptor antagonists, leukotriene A(LTA) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, Hantagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

7244753, Jul 17, 2007

Jul 29, 2003

10/628375

David S. Garvey - Dover MA, US
Subhash P. Khanapure - Clinton MA, US
Ramani R. Ranatunge - Lexington MA, US
Stewart K. Richardson - Tolland CT, US
Joseph D. Schroeder - Minneapolis MN, US

NitroMed, Inc. - Lexington MA

A61K 31/427
A61K 31/422
A61K 31/4015
C07D 417/02
C07D 413/02

514365, 514374, 514397, 514424, 514461, 5483761, 5483771

The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.